Analysts expect Agios Pharmaceuticals (NASDAQ:AGIO) to post $13.59 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Agios Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $10.60 million and the highest estimate coming in at $17.00 million. Agios Pharmaceuticals posted sales of $10.51 million during the same quarter last year, which suggests a positive year-over-year growth rate of 29.3%. The company is expected to announce its next quarterly earnings results before the market opens on Thursday, May 3rd.
On average, analysts expect that Agios Pharmaceuticals will report full year sales of $111.39 million for the current financial year, with estimates ranging from $58.30 million to $215.80 million. For the next year, analysts anticipate that the firm will post sales of $311.22 million per share, with estimates ranging from $85.66 million to $734.10 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. The firm had revenue of $9.80 million during the quarter, compared to analysts’ expectations of $12.65 million. During the same quarter in the previous year, the firm posted ($1.34) EPS. Agios Pharmaceuticals’s revenue was down 56.7% compared to the same quarter last year.
A number of research firms have issued reports on AGIO. Credit Suisse Group set a $95.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday. ValuEngine upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. UBS cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 14th. JPMorgan Chase boosted their price target on shares of Agios Pharmaceuticals from $76.00 to $85.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Finally, Oppenheimer cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 14th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Agios Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $87.00.
In related news, CEO David P. Schenkein sold 53,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $73.16, for a total transaction of $3,877,480.00. Following the transaction, the chief executive officer now owns 53,000 shares in the company, valued at $3,877,480. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Christopher Bowden sold 2,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.75, for a total transaction of $157,500.00. Following the transaction, the insider now owns 2,881 shares in the company, valued at approximately $226,878.75. The disclosure for this sale can be found here. Insiders have sold 210,880 shares of company stock worth $16,368,948 in the last quarter. 5.43% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the stock. Virtus Fund Advisers LLC bought a new stake in Agios Pharmaceuticals during the fourth quarter worth about $379,000. Geode Capital Management LLC boosted its stake in Agios Pharmaceuticals by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 369,512 shares of the biopharmaceutical company’s stock worth $21,125,000 after acquiring an additional 4,073 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Agios Pharmaceuticals by 19.7% during the third quarter. Schwab Charles Investment Management Inc. now owns 115,995 shares of the biopharmaceutical company’s stock worth $7,743,000 after acquiring an additional 19,129 shares in the last quarter. First Trust Advisors LP boosted its stake in Agios Pharmaceuticals by 26.3% during the fourth quarter. First Trust Advisors LP now owns 813,647 shares of the biopharmaceutical company’s stock worth $46,516,000 after acquiring an additional 169,331 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Agios Pharmaceuticals by 41.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock worth $149,000 after acquiring an additional 762 shares in the last quarter. 82.41% of the stock is currently owned by institutional investors and hedge funds.
AGIO stock opened at $87.33 on Friday. Agios Pharmaceuticals has a 12-month low of $45.11 and a 12-month high of $89.33. The stock has a market capitalization of $4,834.36, a price-to-earnings ratio of -12.94 and a beta of 1.98.
ILLEGAL ACTIVITY WARNING: “$13.59 Million in Sales Expected for Agios Pharmaceuticals (AGIO) This Quarter” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://ledgergazette.com/2018/04/14/13-59-million-in-sales-expected-for-agios-pharmaceuticals-agio-this-quarter.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.